The Fondation pour la science is a non-profit, private entity. Its aim is to promote the Weizmann Institute of Science in Belgium and to support its research projects via appropriate public relations activities as well as selective fund raising, in particular in the form of sponsorships, donations and legacies.

One of the Foundation’s regular activites is the sponsoring of promising students attending Belgian secondary schools, who qualify for participation in the annual 4 weeks International Scientific Summer School (ISSI) on the Weizmann Institute of Science campus, before continuing their tertiary education in science. This year two promising young women have been selected.

The Foundation is chaired by Mr Christian Hendboeg.
Mrs Diane Culer, Prof. Pierre Klees, Prof Maurice Sosnowski, Mr Paul de Schietere de Lophem, Mr Eric Hemeleers and Mr Roland Louis are directors.
The Belgian Foundation was founded in 2006, replacing the Belgian Committee, which had been established in 1973 by Prof. Georges Schnek, who also served as the first Secretary General until 1979. He was succeeded by Mr Louis Culer, who held this position for 20 years until 1999, followed by Prof. Marc van Montagu until June 2006.

Among the former Chairmen of the Committee were the former Belgian Prime Minister Theo Lefèvre (1973-1975), Prof. Piet de Somer, Rector of the “Katolieke Universiteit Leuven” (1975-1980) and Prof. Jean Brachet (1980-1972). Two Nobel Laureates, Prof. Christian de Duve and Prof. Ilya Prigogine, were members of the Academic Council.

TOOKAD®, Invented at the Weizmann Institute of Science, Gains European Approval for Prostate Cancer

The treatment, approved for use in 31 countries, is now being marketed in Germany, Italy, Israel and Mexico


TOOKAD® optic fibers illuminate only the cancerous regions, leaving healthy tissue alone

Steba Biotech, a privately-owned company, in collaboration with scientists at the Weizmann Institute of Science, has conduct extensive research and development on TOOKAD®, and has received marketing authorization to make TOOKAD® available in 31 European countries. Following this regulatory approval, the first patients are currently being treated in top Israeli, German, English and Italian medical centers.

Blue-Sky Dye Spells Hope for Improving Heart Function

The small molecule reduces damaging inflammation and improves heart function in mouse models of heart attack


Also in:

Life SciencesDisease, Drugs & DiagnosticsMolecular and Cell BiologyPersonalized Medicine

Injured heart following myocardial infarction. Healthy cardiomyocytes are stained in green. Injured area is stained in red

One day “blue blood” might be synonymous with a way to help the heart heal. Researchers at the Weizmann Institute of Science found that a non-toxic blue dye used in biology labs can help repair damaged heart tissue in mice. The results of this research were recently published in the Journal of Clinical Investigation (JCI) Insight.

The 11th President of the Weizmann Institute and Four New Vice Presidents Take Office

Institute President, Prof. Alon Chen: “Our alumni provide the foundations of Israel’s booming economy.”


The new team (l-r) Profs. Roee Ozeri, Ziv Reich, Alon Chen, Irit Sagi and Alon Harmelin

The 11th president of the Weizmann Institute of Science, Prof. Alon Chen, took office today. He is joined by four new vice presidents, all of whom assumed their new mantles today. “The Weizmann Institute is a world-leading research institution that generates transformative knowledge and educates the scientists of tomorrow,” said Prof. Chen in his recent speech before the Annual International Board.  “Our alumni embark on careers in high-tech and biotech, and in academia, providing the foundations of Israel’s booming economy, just as Chaim Weizmann envisioned. As we reach the milestone of seventy years since the establishment of the Weizmann Institute, I believe it’s safe to say that we have indeed lived up to Chaim Weizmann’s expectations. Perhaps we have even exceeded them.” (The full text of Prof. Alon’s speech can be found here.)

A better vaccine against Ebola?

Weizmann study may show the way



A vaccine that protects against Ebola—one of the world’s deadliest viral diseases—was recently approved by the European Medicines Agency (EMA), the first time any immunization against Ebola has passed this hurdle. But while this vaccine, first developed by Merck in 2003, has already helped to control deadly outbreaks of the virus, no one knows exactly how Ebola vaccines activate the body’s immune system to fight the virus, or whether such vaccines provide long-term protection.

Q&A with Prof. Alon Chen

A lively conversation with the Weizmann Institute’s incoming President


DATE: OCTOBER 23, 2019
Prof. Alon Chen

Prof. Alon Chen

Prof. Alon Chen enters office as the next President of the Weizmann Institute on December 1. A  world-renowned neuroscientist with a focus on stress, he has elucidated many mechanisms by which the brain regulates the body’s response to stressful challenges, and how this response is linked to psychiatric disorders.